WO2004089326A1 - Preparations cosmetiques ou dermatologiques contenant une combinaison de creatinine, de creatine et de quinones biologiques - Google Patents

Preparations cosmetiques ou dermatologiques contenant une combinaison de creatinine, de creatine et de quinones biologiques Download PDF

Info

Publication number
WO2004089326A1
WO2004089326A1 PCT/EP2004/050482 EP2004050482W WO2004089326A1 WO 2004089326 A1 WO2004089326 A1 WO 2004089326A1 EP 2004050482 W EP2004050482 W EP 2004050482W WO 2004089326 A1 WO2004089326 A1 WO 2004089326A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
preparations
cosmetic
derivatives
prophylaxis
Prior art date
Application number
PCT/EP2004/050482
Other languages
German (de)
English (en)
Inventor
Uwe Schoenrock
Volker Schreiner
Franz Staeb
Inge Kruse
Helga Biergiesser
Holger Lenz
Claudia Mundt
Melanie Schmidt
Thomas Blatt
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2004089326A1 publication Critical patent/WO2004089326A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to the use of combinations of creatinine and / or creatinine derivatives with creatine and / or its derivatives with bioquinones in cosmetic or dermatological preparations for the treatment and prophylaxis of the symptoms of UV and or ozone-induced skin damage and of inflammatory and degenerative skin conditions.
  • Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are intended to protect against environmental influences, especially sun and wind, and to delay skin aging.
  • Chronological skin aging is caused, for example, by endogenous, genetically determined factors.
  • the following structural damage and functional disorders occur in the epidermis and dermis due to aging, which can also fall under the term "senile xerosis”: a) dryness, roughness and the formation of wrinkles due to dryness, b) itching and c) reduced regreasing due to sebum glands (eg after washing).
  • Exogenous factors such as UV light and chemical pollutants can be cumulative and e.g. accelerate or complement the endogenous aging processes.
  • exogenous factors e.g. to the following structural damage and functional disorders in the skin that go beyond the extent and quality of the damage caused by chronological aging: d) visible vasodilation (telangiectasias, cuperosis); e) flaccidity and wrinkling; f) local hyper-, hypo- and incorrect pigmentations (e.g. age spots) and g) increased susceptibility to mechanical stress (e.g. cracking).
  • the present invention relates in particular to products for the care of naturally aged skin and for the treatment of the consequential damage caused by light aging, in particular the phenomena listed under a) to g).
  • Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • Retinoids vitamin A acid and / or its derivatives
  • their effect on structural damage is limited in scope.
  • the use of products containing vitamin A acid often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the present invention relates to cosmetic preparations with effective protection against harmful oxidation processes in the skin, but also for protecting cosmetic preparations themselves or for protecting the constituents of cosmetic preparations against harmful oxidation processes.
  • UVC range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • Numerous compounds are known for protection against UVB radiation, which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole.
  • UVA range It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • Such photochemical reaction products are predominantly free radical compounds, for example hydroxy radicals.
  • Undefined radical photo products which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen that is normally present (radical ground state). However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV, which in turn can then oxidatively intervene in the biochemical processes. In order to prevent these reactions, additional antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
  • vitamin E a substance with a known antioxidant effect, in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the invention was therefore also to provide cosmetic, dermatological and pharmaceutical active substances and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably PLD.
  • Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
  • antioxidants and / or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
  • antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidant activity in light protection formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the present invention was therefore to find ways which avoid the disadvantages of the prior art. In particular, the effect of remedying the damage associated with endogenous, chronological and exogenous skin aging and the prophylaxis should be permanent, sustainable and without the risk of side effects. The object of the present invention was to remedy these shortcomings.
  • the invention also includes the use of such preparations for the prophylaxis and / or treatment of inflammatory skin conditions and / or for skin protection in the case of sensitive and dry skin (such as, for example, atopic eczema, seborrheic eczema, polymorphic light dermatosis, psoriasis, vitiligo, Wound healing disorders, itching, sensitive or irritated skin, light-induced skin damage and UV-induced immunosuppression, changes in desquamation, changes in normal fibroblast and keratinocyte proliferation, changes in normal fibroblast and keratinocyte differentiation, deficient, sensitive or hypoactive skin conditions, sensitive or hypoactive skin conditions, sensitive, or hypoactive skin conditions, sensitive, or hypoactive skin conditions, sensitive, or hypoactive skin conditions and to reduce skin thickness).
  • sensitive and dry skin such as, for example, atopic eczema, seborrheic eczema, polymorphic light dermatosis, psori
  • the invention comprises the use of such preparations for the treatment and prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin, for.
  • degenerative symptoms of the skin such as age spots, wrinkles, telangiectasias, sagging skin, loss of elasticity, as well as loss of the epidermal and dermal cell layers, the components of the connective tissue, the rete cones and capillary vessels), so-called skin luster and fatigue (skin sagging and / or skin fatigue), increased activation of proteolytic enzymes in the skin such as B.
  • Metalloproteinases disorders of normal collagen, hyaluronic acid, elastin and glycosaminoglycan homeostasis and normal skin regeneration, changes in normal fibroblast and keratinocyte proliferation. Changes in normal fibroblast and keratinocyte differentiation, deficiency symptoms of the intracellular DNA synthesis (especially in deficient or hypoactive skin conditions), environmental (caused by smoking, smog, reactive oxygen species, free radicals and the like) negative changes in the skin and / or the appendages of the skin.
  • Also according to the invention is the use of such preparations for the treatment and / or prophylaxis of pigmentation disorders, for increasing ceramide biosynthesis (such as changes in the ceramide, lipid and energy metabolism of healthy skin), for strengthening the barrier function of the skin (such as. B. Horn layer barrier disorders, changes in normal lipid peroxidation, changes in transepidermal water loss and normal moisture content of the skin), for the treatment and / or prophylaxis of disorders of the normal skin pH and the osmolytic balance, for the treatment and / or prophylaxis of deviations from normal cell-cell communication in the skin (e.g. intercellular communication via mediators and / or via mechanical / physiological connections).
  • ceramide biosynthesis such as changes in the ceramide, lipid and energy metabolism of healthy skin
  • barrier function of the skin such as. B. Horn layer barrier disorders, changes in normal lipid peroxidation, changes in transepidermal water loss and normal moisture content of the skin
  • compositions for the treatment and / or prophylaxis of functional disorders of the skin appendages for example hair loss, improved hair growth, improved hair gloss, improved hair structure, seborrheic symptoms, oily skin, oily hair, comedones, but also dandruff.
  • Preparations and uses according to the invention are preferably characterized in that coenzyme Q10 is contained as bioquinone.
  • Preparations and uses according to the invention are particularly preferably characterized in that coenzyme Q10 and vegetable and animal extracts containing the same are contained in cosmetic or topical dermatological preparations in concentrations of 0.001-30% by weight, particularly preferably 0.01-1% by weight based on the total weight of the preparations and the content of creatinine and / or its derivatives 0.001-50% by weight, preferably 0.1-10% by weight and the content of creatine and its derivatives 0.001-50% by weight , preferably 0.1-10% by weight, based on the total weight of the preparations.
  • Creatinine is contained in meat extract and bouillon cubes.
  • Creatinine is formed in aqueous solution. It arises in the organism through transamidation of L-arginine on glycine to guanidinoacetic acid and its subsequent methylation using S-adenosylmethionine (through guanidinoacetate methyltransferase). Creatine is thought to be an appetite-enhancing component of beef and meat extract. Adding creatine to food increases physical performance.
  • the weight ratio of creatinine to creatine in the range from 50: 1 to 1:50, preferably from 10: 1 to 1:10, particularly preferably from 2: 1 to 1: 2.
  • the preferred derivative is creatine phosphate, which has the following structure:
  • Creatine phosphate is present in the working muscle Adenosine 5'-diphosphate under the influence of the enzyme creatine kinase adenosine 5'-triphosphate (ATP) and creatine; the reverse reaction takes place in the resting muscle. But also creatine sulfate, creatine acetate, creatine ascorbate and the derivatives esterified on the carboxyl group with mono- or polyfunctional alcohols lead to advantageous embodiments of the invention.
  • Coenzyme Q-10 for example, is characterized by the following structural formula:
  • Ubiquinones serve the organisms as electron carriers in the respiratory chain. They are located in the mitochondria where they enable the cyclic oxidation and reduction of the substrates of the citric acid cycle. Plastoquinones have the general structural formula
  • Cosmetic preparations with coenzyme Q-10 from DE-A-33 09 850 are known which are used for the treatment of skin diseases, for the prophylaxis of dystrophic and dysmabolic conditions of the skin and for use in the case of chemical and physical respiratory damage or in the case of delayed respiration Age and wear are suitable.
  • coenzyme Q-10 for cosmetics is described in Japanese laid-open publication 58, 180, 410. It is said to activate skin cell metabolism and suppress oxidation. As a result, coenzyme Q10 has an important function in the prevention of skin damage from UV rays and the prevention of skin aging.
  • JP2000 / 247866 describes skin cosmetics with a content of creatine and / or creatinine, which can be used as a cream or as a milky lotion, the preparations in question being attributed excellent skin-care properties.
  • this document could not pave the way for the present invention.
  • WO00 / 33787 describes the use of creatinine as an effective component of deodorants. This document also could not pave the way to the present invention.
  • EP-A 565 010 describes hair growth and hair dye preparations containing creatine phosphate. This document also could not pave the way to the present invention.
  • the combination of active substances according to the invention or cosmetic or topical dermatological preparations with an effective content of active substance combination according to the invention also serves, surprisingly, to calm sensitive or irritated skin to stimulate collagen, hyaluronic acid, elastin synthesis to stimulate intracellular DNA synthesis, in particular with deficient or hypoactive skin conditions.
  • to increase cell renewal and regeneration of the skin to increase the skin's own protection and repair mechanisms (for example for dysfunctional enzymes, DNA, lipids, proteins) for pre-treatment and post-treatment with topical application of laser and abrasive treatments, e.g. B. serve the reduction of skin folds and scars to counteract the resulting skin irritation and to promote the regeneration processes in the injured skin.
  • Effects according to the invention lie in the stabilization of the energy metabolism in the sense of a synergism between the components creatine, creatinine and coenzyme Q10 according to the invention in comparison to creatine and creatinine alone.
  • the improved energy level of the skin cells can have a significantly better effect for prophylaxis and Treatment of degenerative skin and hair symptoms (wrinkles, sagging, degeneration, age spots, circulatory disorders, itching, sensitivity to stress, brittleness) can be achieved.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), arthioglucose, propylthiouracil and other thiols (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-
  • thioredoxin glutathione , Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters) as well as their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, pentathione, hexa-, imine
  • low tolerable doses e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • -hydroxy acids e.g.
  • citric acid lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin , EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives eg ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives alanine diacetic acid, flavonoids, taurine and derivatives, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate , Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (eg vitamin E acetate), as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajakharzenic acid, noredihydroxychloric acid
  • stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the prophylaxis or the cosmetic or dermatological treatment with the active substance combinations used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active substance combination used according to the invention is carried out in the usual way, in such a way that the active substance used according to the invention or the cosmetic ones or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient combination used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • the active ingredient combination used according to the invention into aqueous systems or surfactant preparations for cleaning and also care of the skin and hair.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • medicaments in an effective concentration.
  • cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It is possibly possible and advantageous to add the compositions according to the invention as the basis for pharmaceutical formulations use.
  • cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • these preferably additionally contain at least one UVA filter substance and / or at least one UVB filter substance and / or at least one inorganic pigment.
  • Preparations according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances e.g. to call:
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
  • 2-phenylbenzimidazole-5-sulfonic acid and its salts e.g. Sodium, potassium or triethanolammonium salts
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene-methyl) sulfonic acid and their salts.
  • UVB filters which can be used according to the invention, is of course not intended to be limiting.
  • the invention also relates to the combination of a UVA film according to the invention. ters with a UVB filter or a cosmetic or dermatological preparation according to the invention, which also contains a UVB filter.
  • UVA filters in preparations according to the invention, which are usually contained in cosmetic and / or dermatological preparations.
  • Such filter substances are preferably derivatives of dibenzoylmethane, in particular 1 - (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4 '-isopropylphenyl) propane-1,3-dione. Preparations containing these combinations are also the subject of the invention.
  • the same amounts of UVA filter substances that were mentioned for UVB filter substances can be used.
  • Cosmetic and / or dermatological preparations in the sense of the present invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. Pigments based on titanium dioxide are particularly preferred. The amounts mentioned for the above combinations can be used.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic active ingredients, auxiliaries and / or additives as are usually used in such preparations, e.g. Antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common ingredients a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic active ingredients e.g. Antioxidants, preservatives, bactericides, perfumes, anti-foaming substances, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other common ingredients
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably Ri- zinusöl;
  • Fats, waxes and other natural and synthetic fat bodies preferably
  • Esters of fatty acids with low C alcohols e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with lower C- alkanoic acids
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the sense of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethylhexyluryl, 2-ethylhexyl palylate, Octyldodecyl palmitate, olefin oleate, olefin erucate, erucyl oleate, erucyl erucate as well as synthetic, semi-synthetic and natural mixtures of such esters, for example Jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, Palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is selected from the group 2-ethylhexyl advantageous Octyldo- decanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12 ⁇ 5 -alkyl, Ca Pryl-capric acid triglyceride, dicaprylyl ether.
  • the oil phase can also advantageously have a content of cyclic or linear silicon oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Mixtures of cyclomethicone and isotridecyl isononanoate, of cyclomethicone and 2-ethylhexyl isostearate are also particularly advantageous.
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or - monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethylene glycol monomethyl or monoethyl ether and analog products, furthermore alcohols low Riger C number, for example ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which or which can advantageously be selected from the group silicon dioxide, aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose , particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group
  • Gels used in the present invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener which is preferably silicon dioxide or an aluminum silicate in the case of oily-alcoholic gels, and is preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • low C number alcohols e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener which is preferably silicon dioxide or an aluminum silicate in the case of oily-alcoholic gels, and is preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • Fixed pens contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters.
  • Usual base materials which are suitable for use as cosmetic sticks in the sense of the present invention are liquid oils (for example paraffin oils, castor oil, isopropyl myristate), semi-solid components (for example petroleum jelly, lanolin), solid components (for example beeswax, ceresin and microcrystallines) Waxes or ozokerite) and high-melting waxes (e.g. carnauba wax, candelilla wax)
  • liquid oils for example paraffin oils, castor oil, isopropyl myristate
  • semi-solid components for example petroleum jelly, lanolin
  • solid components for example beeswax, ceresin and microcrystallines
  • Waxes or ozokerite for example beeswax, ceresin and microcrystallines
  • high-melting waxes e.g. carnauba wax, candelilla wax
  • Suitable blowing agents for cosmetic and / or dermatological preparations which can be sprayed from aerosol containers for the purposes of the present invention are the customary known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Cosmetic preparations in the sense of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents usually used therefor, preferably water, and also organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, Hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. B. aluminum silicates such as bentonite, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickener is contained in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • Cosmetic preparations according to the invention are listed below by way of example, all of which generate the described advantages of high and long-lasting skin moisture retention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des préparations cosmétiques ou dermatologiques contenant une combinaison d'agents actifs à base de créatinine et/ou de ses dérivés avec de la créatine et/ou ses dérivés et des quinones biologiques, ainsi que des extraits végétaux et animaux les contenant.
PCT/EP2004/050482 2003-04-10 2004-04-07 Preparations cosmetiques ou dermatologiques contenant une combinaison de creatinine, de creatine et de quinones biologiques WO2004089326A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10316666.1 2003-04-10
DE10316666.1A DE10316666B4 (de) 2003-04-10 2003-04-10 Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10

Publications (1)

Publication Number Publication Date
WO2004089326A1 true WO2004089326A1 (fr) 2004-10-21

Family

ID=33039022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050482 WO2004089326A1 (fr) 2003-04-10 2004-04-07 Preparations cosmetiques ou dermatologiques contenant une combinaison de creatinine, de creatine et de quinones biologiques

Country Status (2)

Country Link
DE (1) DE10316666B4 (fr)
WO (1) WO2004089326A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747786A3 (fr) * 2005-07-25 2007-04-25 Perdix Eurogroup S.L. Produit naturel crémeux avec des qualités anti-vitiligo
EP2022472A1 (fr) * 2007-08-07 2009-02-11 KPSS-Kao Professional Salon Services GmbH Composition de conditionnement pour cheveux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007057543A1 (de) * 2007-11-29 2009-06-04 Merck Patent Gmbh a-Aminosäurederivate zur Löslichkeitsverbesserung

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565010A1 (fr) * 1992-04-10 1993-10-13 Antonio Rizzo Composition par la teinture et la croissance des cheveux
WO2001000203A1 (fr) * 1999-06-25 2001-01-04 Avicena Group, Inc. Utilisation de creatine ou de composes de creatine pour la preservation de la peau
JP2001114701A (ja) * 1999-10-12 2001-04-24 Lion Corp 皮膚外用剤
WO2002002075A1 (fr) * 2000-07-06 2002-01-10 Beiersdorf Ag Utilisation de creatine et/ou de derives de creatine dans des preparations cosmetiques ou dermatologues
WO2002011717A1 (fr) * 2000-08-07 2002-02-14 Juvenon, Inc. Cosmetiques destines a aider le metabolisme cutane
WO2002069740A1 (fr) * 2001-03-02 2002-09-12 The Howard Foundation Compositions contenant de la creatine et de la creatinine
WO2002076408A2 (fr) * 2001-03-24 2002-10-03 Wella Aktiengesellschaft Utilisation d'agents renfermant de la creatine, de la creatinine et/ou des derives de celles-ci afin de renforcer des fibres de keratine et d'ameliorer leur structure
DE10119608A1 (de) * 2001-04-21 2002-10-24 Goldschmidt Ag Th Verwendung von Kreatin und/oder Kreatin-Derivaten in Haarbehandlungsmitteln und Haarnachbehandlungsmitteln zum Schutz vor Schäden durch chemische Behandlung und zur Reparatur bereits geschädigter Haare
WO2003005988A1 (fr) * 2001-07-07 2003-01-23 Beiersdorf Ag Preparations cosmetiques et dermatologiques a la creatine utilisees dans le traitement et la prevention active de la peau seche et d'autres modifications negatives de l'homeostase physiologique des peaux saines
WO2003011241A1 (fr) * 2001-07-25 2003-02-13 Beiersdorf Ag Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702688A (en) * 1986-12-23 1997-12-30 Tristrata Technology, Inc. Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
DE19914646A1 (de) * 1999-03-31 2000-10-05 Kapitz Carl Heinz Wirkstoffkombination für Mensch und Tier
US20020044913A1 (en) * 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
DE10048261A1 (de) * 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxamin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10048260A1 (de) * 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10120315A1 (de) * 2001-04-26 2002-10-31 Beiersdorf Ag Verwendung von Klee-Extrakt in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe gegen und Behandlung von degenerativen Hauterscheinungen
DE10121375B4 (de) * 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10127717A1 (de) * 2001-06-07 2002-12-12 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10131796A1 (de) * 2001-06-30 2003-01-16 Beiersdorf Ag Verwendung von Cardiolipin in kosmetischen oder dermatologischen Zubereitungen
DE10132953A1 (de) * 2001-07-06 2003-01-16 Beiersdorf Ag Verwendung von Hopfen-bzw. Hopfen-Malz-Extrakten in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe gegen und Behandlung von degenerativen Hauterscheinungen
DE10136077A1 (de) * 2001-07-25 2003-02-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
ITRM20020296A1 (it) * 2002-05-27 2003-11-27 Licrea S R L Sale di creatina ad aumento potere nutrizionale, antiossidante e terapeutico e composizioni che lo contengono.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565010A1 (fr) * 1992-04-10 1993-10-13 Antonio Rizzo Composition par la teinture et la croissance des cheveux
WO2001000203A1 (fr) * 1999-06-25 2001-01-04 Avicena Group, Inc. Utilisation de creatine ou de composes de creatine pour la preservation de la peau
JP2001114701A (ja) * 1999-10-12 2001-04-24 Lion Corp 皮膚外用剤
WO2002002075A1 (fr) * 2000-07-06 2002-01-10 Beiersdorf Ag Utilisation de creatine et/ou de derives de creatine dans des preparations cosmetiques ou dermatologues
WO2002011717A1 (fr) * 2000-08-07 2002-02-14 Juvenon, Inc. Cosmetiques destines a aider le metabolisme cutane
WO2002069740A1 (fr) * 2001-03-02 2002-09-12 The Howard Foundation Compositions contenant de la creatine et de la creatinine
WO2002076408A2 (fr) * 2001-03-24 2002-10-03 Wella Aktiengesellschaft Utilisation d'agents renfermant de la creatine, de la creatinine et/ou des derives de celles-ci afin de renforcer des fibres de keratine et d'ameliorer leur structure
DE10119608A1 (de) * 2001-04-21 2002-10-24 Goldschmidt Ag Th Verwendung von Kreatin und/oder Kreatin-Derivaten in Haarbehandlungsmitteln und Haarnachbehandlungsmitteln zum Schutz vor Schäden durch chemische Behandlung und zur Reparatur bereits geschädigter Haare
WO2003005988A1 (fr) * 2001-07-07 2003-01-23 Beiersdorf Ag Preparations cosmetiques et dermatologiques a la creatine utilisees dans le traitement et la prevention active de la peau seche et d'autres modifications negatives de l'homeostase physiologique des peaux saines
WO2003011241A1 (fr) * 2001-07-25 2003-02-13 Beiersdorf Ag Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHAATH, NADIM A. ET AL SHAATH, NADIM A. ET AL: "An exciting new ingredient comes to sun care An exciting new ingredient comes to sun care", XP002292079, retrieved from STN Database accession no. 2002:929988 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 21 3 August 2001 (2001-08-03) *
SOAP & COSMETICS , 78(8), 39-40, 42 CODEN: SPCMFG; ISSN: 1523-9225 SOAP & COSMETICS , 78(8), 39-40, 42 CODEN: SPCMFG; ISSN: 1523-9225, 2002 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747786A3 (fr) * 2005-07-25 2007-04-25 Perdix Eurogroup S.L. Produit naturel crémeux avec des qualités anti-vitiligo
EP2022472A1 (fr) * 2007-08-07 2009-02-11 KPSS-Kao Professional Salon Services GmbH Composition de conditionnement pour cheveux
EP2022468A1 (fr) * 2007-08-07 2009-02-11 KPSS-Kao Professional Salon Services GmbH Composition de conditionnement des cheveux

Also Published As

Publication number Publication date
DE10316666B4 (de) 2015-04-09
DE10316666A1 (de) 2004-10-28

Similar Documents

Publication Publication Date Title
EP1642559B1 (fr) Utilisation de créatine et/ou de dérivés de créatine et de l'acide folique dans des préparations cosmétiques ou dermatologiques
EP1594455B1 (fr) Preparations cosmetiques ou dermatologiques contenant de la creatine, de la creatinine et / ou leurs derives en combinaison avec des extraits de germe de graines de soja
EP0945126B1 (fr) Composition cosmétique ou dermatologique contenant de la carnitine et/ou un acylcarnitine et au moins un antioxydant
EP0716847A1 (fr) Compositions cosmétiques ou dermatologiques contenant des dérivés d'acide cinnamique et des flavonoides
DE19806947A1 (de) Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
EP1194115A1 (fr) Agent pour usage topique a action protectrice et regeneratrice, comprenant de l'idebenone
WO2002009652A2 (fr) Utilisation d'associations contenant des carnitines
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
WO2005027866A1 (fr) Utilisation de licochalcone a ou d'un extrait contenant de la licochalcone a a base de radix glycyrrhizae inflatae pour lutter contre le vieillissement de la peau
WO2002026206A1 (fr) Preparations cosmetiques et dermatologiques contenant de l'aminoguanidine
DE102004032837A1 (de) Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
DE10136076A1 (de) Verwendung von Kreatinin und/oder Kreatininderivaten in kosmetischen oder dermatologischen Zubereitungen
EP1084701A1 (fr) Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
EP0963754A1 (fr) Composition cosmétique ou dermatologique contenant de la carnitine et/ou un acylcarnitine et au moins un retinoide
EP0945127A2 (fr) Utilisation de l'acylcarnitine
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
DE10158076B4 (de) Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
DE10127717A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE102017212649A1 (de) Verwendung von N-(4-amino-2-methylchinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamid zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE10127432A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase